Patients do well with it. The durability is not a year in my experience outside of cases where there is a defined nerve trauma without ongoing structural issues. I've used it for a lot of different things but it's primarily because it is easy for me and the patient more than something I believe strongly in.
I struggle with the mechanism of action and hand waving about resetting central sensitization/plasticity/etc.
The multifidus data is challenging as I cannot reconcile it with the Reactiv-8 data which shows a much longer wash-in period. The SPR study feels to me me like a lot of patients that probably didn't get the Lobel HEP/core regimen. There's a lot of differences though in the stimulation parameters/etc, but still, it's an annoying discrepancy.
I don't like the business model/pricing as it could be done in a clinic room but is not due to the site of service differential making the margin better in a facility.
It shows me a lot of promise but PNS is still a game of compromises and I suspect will have a course adjustment when CMS starts paying attention to it.